The Inflation Reduction Act will likely change incentives surrounding single-indication launches and postapproval research for additional indications in small molecule drugs, affecting patient access.
James Motyka, PharmD
Advertisement
Articles by James Motyka, PharmD
Advertisement
Latest Updated Articles
Unintended Consequences of the Inflation Reduction Act: Clinical Development Toward Subsequent IndicationsPublished: February 2nd 2024 | Updated:
Advertisement
Advertisement
